Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42312   clinical trials with a EudraCT protocol, of which   6968   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-000719-15
    Sponsor's Protocol Code Number:CNTO1959PSO3001
    National Competent Authority:Poland - Office for Medicinal Products
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2014-09-22
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedPoland - Office for Medicinal Products
    A.2EudraCT number2014-000719-15
    A.3Full title of the trial
    A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis
    Wieloośrodkowe, randomizowane, podwójnie zaślepione badanie kliniczne fazy 3 z porównaniem względem placebo oraz komparatora aktywnego, służące ocenie skuteczności i bezpieczeństwa guselkumabu w leczeniu pacjentów z umiarkowaną do ciężkiej łuszczycą plackowatą
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study of Guselkumab in the Treatment of Participants with Moderate to Severe Plaque-Type Psoriasis
    Badanie guselkumabu w leczeniu pacjentów z umiarkowaną do ciężkiej
    łuszczycą plackowatą.
    A.3.2Name or abbreviated title of the trial where available
    VOYAGE 1
    A.4.1Sponsor's protocol code numberCNTO1959PSO3001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJanssen-Cilag International N.V.
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportJanssen Research & Development, LLC
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationJanssen-Cilag International N.V.
    B.5.2Functional name of contact pointClinical Registry group
    B.5.3 Address:
    B.5.3.1Street AddressArchimedesweg 29
    B.5.3.2Town/ cityLeiden
    B.5.3.3Post code2333 CM
    B.5.3.4CountryNetherlands
    B.5.4Telephone number+31715242166
    B.5.5Fax number+31715242110
    B.5.6E-mailClinicalTrialsEU@its.jnj.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGuselkumab
    D.3.2Product code CNTO1959
    D.3.4Pharmaceutical form Solution for injection in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGuselkumab
    D.3.9.2Current sponsor codeCNTO1959
    D.3.9.3Other descriptive nameGUSELKUMAB
    D.3.9.4EV Substance CodeSUB130392
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Yes
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeMonoclonal antibody
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Humira
    D.2.1.1.2Name of the Marketing Authorisation holderAbbVie Ltd
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameHumira
    D.3.4Pharmaceutical form Solution for injection in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNADALIMUMAB
    D.3.9.1CAS number 331731-18-1
    D.3.9.4EV Substance CodeSUB20016
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeMonoclonal antibody
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection in pre-filled syringe
    D.8.4Route of administration of the placeboSubcutaneous use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection in pre-filled syringe
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Moderate to Severe Plaque Type Psoriasis
    Umiarkowana i ciężka postać łuszczycy plackowatej
    E.1.1.1Medical condition in easily understood language
    Psoriasis
    Luszczyca
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10037153
    E.1.2Term Psoriasis
    E.1.2System Organ Class 10040785 - Skin and subcutaneous tissue disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    • To evaluate the efficacy of guselkumab for the treatment of subjects with moderate to severe plaque-type psoriasis.
    • To assess the safety and tolerability of guselkumab in subjects with moderate to severe plaque-type psoriasis.
    • Ocena skuteczności guselkumabu w leczeniu pacjentów z
    umiarkowaną do ciężkiej łuszczycą plackowatą.
    • Ocena bezpieczeństwa i tolerancji leczenia guselkumabem u
    pacjentów z umiarkowaną do ciężkiej łuszczycą plackowatą
    E.2.2Secondary objectives of the trial
    • To compare the efficacy of guselkumab to adalimumab in subjects with moderate to severe plaque type psoriasis.
    • To evaluate the effect of treatment with guselkumab on other measures of signs and symptoms of psoriasis.
    • To evaluate the effect of treatment with guselkumab on health-related quality of life.
    • Porównanie skuteczności guselkumabu ze skutecznością
    adalimumabu u pacjentów z umiarkowaną do ciężkiej łuszczycą
    plackowatą.
    • Ocena wpływu leczenia guselkumabem na inne miary oznak i
    objawów łuszczycy.
    • Ocena wpływu leczenia guselkumabem na zależną od stanu zdrowia
    jakość życia.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Skin biopsy samples will be collected from a subset of subjects who consent to participate in the optional biopsy substudy. Enrollment in the biopsy substudy will be optional and will include approximately 90 subjects at selected sites. Only subjects who consent to participate in the optional biopsy substudy will undergo collection of these samples. Biopsies will be used for assessment of RNA expression. Protocol A1, dated 12 February 2015
    Próbki biopsji skóry pobrane zostaną od Pacjentów, którzy wyrażą zgodę
    na udział w podbadaniu. Włączenie do podbadania będzie opcjonalne i
    będzie zawierało ok. 90 pacjentów w wybranych ośrodkach badawczych.
    Próbka krwi zostanie pobrana od pacjentów, którzy udzielą dodatkowej
    zgody na udział w podbadaniu. Próbki biopsji będą ocenione pod kątem
    ekspresji RNA.
    Wersja podbadań: Protokół A1, wersja finalna z dnia 12 lutego 2015
    E.3Principal inclusion criteria
    - Have a diagnosis of plaque-type psoriasis (with or without psoriatic arthritis) at least 6 months before the first administration of study agent
    - Have a Psoriasis Area and Severity Index (PASI) greater than or equal to (>=) 12 at Screening and at Baseline
    - Have an Investigator’s Global Assessment (IGA) score >=3 at Screening and at Baseline
    - Have an involved body surface area (BSA) >=10 percent(%) at Screening and at Baseline
    - Must be a candidate for either systemic therapy or phototherapy for psoriasis
    1. Diagnoza łuszczycy plackowatej (wraz lub bez łuszczycowego
    zapalenia stawów) w ciągu 6 miesięcy od pierwszego podania leku
    badanego.
    2. Wartości wskaźnika rozległości i ciężkości łuszczycy (ang. Psoriasis
    Area and Severity Index, PASI) większy lub równy 12 w okresie
    przesiewowym oraz w dniu randomizacji.
    3. Wartość skali „Globalne Ocena Badacza" (IGA) większa lub równa 3
    w okresie przesiewowym oraz w dniu randomizacji.
    4. Zajęcie procesem chorobowym ≥10% całkowitej powierzchni ciała.
    5. Pacjenci muszą być kandydatami do leczenia ogólnoustrojowego lub
    fototerapii łuszczycy i dozwolone jest przyjmowanie przez nich
    uprzednio różnych terapii ogólnoustrojowych lub fototerapii z powodu
    łuszczycy.
    E.4Principal exclusion criteria
    -Participants with nonplaque forms of psoriasis (for example, erythrodermic, guttate, or pustular) or with current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
    - Participants who have ever received guselkumab or adalimumab
    - History or current signs or symptoms of severe, progressive, or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
    - Has any condition that, in the opinion of the investigator, would make participation not be in the best interest (for example, compromise the wellbeing) of the participant or that could prevent, limit, or confound the protocol-specified assessments
    - Is pregnant, nursing, or planning a pregnancy (both men and women) within 5 months following the last administration of study drug
    1. Wcześniejsza historia lub aktualne objawy ciężkiej, postępującej,
    niekontrolowanej choroby układu moczowego, wątroby, sercowonaczyniowego,
    oddechowego, pokarmowego, endokrynologicznego,
    nerwowego, reumatologicznych, psychiatrycznych oraz metabolicznych
    oraz inne schorzenie, które w opinii lekarza powoduje, że uczestnictwo
    w badaniu nie jest w najlepszym interesie pacjenta lub limituje,
    przeszkadza wykonanie procedur wymaganych przez protokół.
    2. Nieplackowata postać łuszczycy (np. kroplista, erytrodermalna,
    krostkowa) oraz obecna łuszczyca indukowana lekami (np. nowa
    łuszczyca lub nasilenie objawów od beta-blokerów, litu oraz blokerów
    kanału wapniowego)
    3. Wcześniejsze przyjmowanie guselkumabu lub adalimumabu
    4. Ciąża, karmienie piersią lub planowanie ciąży (zarówno kobiety jak
    mężczyźni) w ciągu 5 miesięcy od ostatniej dawki leku badanego.
    E.5 End points
    E.5.1Primary end point(s)
    The co-primary endpoints are the proportions of subjects who achieve an IGA score of cleared (0) or minimal (1) and the proportion of subjects who achieve a PASI 90 response at Week 16, comparing the guselkumab group and the placebo group.
    Główne punkty końcowe to odsetek pacjentów, którzy osiągną wynik
    skali IGA 0 lub 1 oraz odsetek pacjentów, którzy osiągną wynik skali
    PASI 90 w tygodniu 16 w porównaniu z grupami pacjentów leczonymi
    placebo oraz guselkumabem
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 16
    Wizyta w tygodniu 16
    E.5.2Secondary end point(s)
    Major Secondary Endpoints

    • The proportion of subjects who achieve an IGA score of cleared (0) at Week 24, comparing the guselkumab group and the adalimumab group.
    • The proportion of subjects who achieve an IGA score of cleared (0) or minimal (1) at Week 24, comparing the guselkumab group and the adalimumab group.
    • The proportion of subjects who achieve a PASI 90 response at Week 24, comparing the guselkumab group and the adalimumab group.
    • The proportion of subjects who achieve an IGA score of cleared (0) at Week 48, comparing the guselkumab group and the adalimumab group.
    • The proportion of subjects who achieve an IGA score of cleared (0) or minimal (1) at Week 48, comparing the guselkumab group and the adalimumab group.
    • The proportion of subjects who achieve a PASI 90 response at Week 48, comparing the guselkumab group and the adalimumab group.
    • The change from baseline in DLQI score at Week 16, comparing the guselkumab group and placebo group.
    • The proportion of subjects who achieve an IGA score of cleared (0) or minimal (1) at Week 16, comparing the guselkumab group and the adalimumab group.
    • The proportion of subjects who achieve a PASI 90 response at Week 16, comparing the guselkumab group and the adalimumab group.
    • The proportion of subjects who achieve a PASI 75 response at Week 16, comparing the guselkumab group and the adalimumab group.
    • The proportion of subjects who achieve an ss-IGA score of absence of disease (0) or very mild disease (1) and have at least a 2-grade improvement from baseline at Week 16, comparing the guselkumab group and placebo group among randomized subjects with scalp psoriasis and an ss-IGA score ≥2 at baseline.
    • The change from baseline in PSSD symptom score at Week 16, comparing the guselkumab group and placebo group.
    • The proportion of subjects who achieve a PSSD symptom score=0 at Week 24, comparing the guselkumab group and the adalimumab group among randomized subjects with a baseline PSSD symptom score ≥1.


    Other Secondary Endpoints


    Placebo Comparisons (Guselkumab vs Placebo and Adalimumab vs Placebo)

    • The proportion of subjects who achieve an IGA score of cleared (0) and the proportion of subjects achieving an IGA score of mild or better (≤2) at Week 16.
    • The proportion of subjects who achieve PASI 100, PASI 75, and PASI 50 responses at Week 16.
    • The percent improvement from baseline in PASI response through Week 16.
    • The proportion of subjects who achieve a DLQI score=0 or 1 at Week 16 among randomized subjects with baseline DLQI>1.
    • The proportion of the subjects with a reduction of 5 or more points in DLQI score at Week 16.
    • The percent improvement from baseline in NAPSI at Week 16 among randomized subjects with nail psoriasis at baseline.
    • The proportion of subjects who achieve an f-PGA score of clear (0) or minimal (1) and have at least a 1 grade improvement from baseline at Week 16 among randomized subjects with an f PGA score ≥2 at baseline.
    • The proportion of subjects who achieve a PSSD symptom score=0 at Week 16 among randomized subjects with a baseline PSSD symptom score ≥1.
    • The proportion of subjects who achieve a PSSD sign score=0 at Week 16 among randomized subjects with a baseline PSSD sign score ≥1.
    • The change from baseline in individual scale score of PSSD components at Week 16.
    • The proportion of subjects who achieve PSSD individual scale score of 0 at Week 16 among randomized subjects with scale score ≥1 at baseline.
    • The proportion of subjects who achieve an hf-PGA score of clear (0) or almost clear (1) and a reduction of at least 2 grades on the hf-PGA scale from baseline at Week 16 among randomized subjects with hand and/or foot psoriasis and an hf-PGA score ≥2 at baseline.

    Guselkumab vs Adalimumab

    • The proportion of subjects who achieve a PASI 75 response and a PASI 100 response at Week 24 and Week 48.
    • The proportion of subjects who achieve an ss-IGA score of absence of disease (0) or very mild disease (1) and have at least a 2-grade improvement from baseline at Week 24 and Week 48 among randomized subjects with scalp psoriasis and an ss-IGA score ≥2 at baseline.
    • The percent improvement from baseline in NAPSI at Week 24 and Week 48 among randomized subjects with nail psoriasis at baseline.
    • The proportion of subjects who achieve an f-PGA score of clear (0) or minimal (1) and have at least 1-grade improvement from baseline at Week 24 and Week 48 among randomized subjects with an f PGA score ≥2 at baseline.
    • The proportion of subjects who achieve an hf-PGA score of clear (0) or almost clear (1) and have at least a 2-grade improvement from baseline at Week 24 and Week 48 among randomized subjects with hand and/or foot psoriasis and an hf-PGA score ≥2 at baseline.
    • The proportion of subjects who achieve a DLQI score=0 or 1 at Week 24 and Week 48 among randomized subjects with baseline DLQI >1.

    See protocol for other secondary endpoints
    • Odsetek pacjentów, którzy osiągną skalę IGA 0 w tygodniu 24 w
    porównaniu z grupami pacjentów leczonymi adalimumabem oraz
    guselkumabem.
    • Odsetek pacjentów, którzy osiągną skalę IGA 0 lub 1 w tygodniu 24 w
    porównaniu z grupami pacjentów leczonymi adalimumabem oraz
    guselkumabem.
    • Odsetek pacjentów, którzy osiągną skalę IGA 0 w tygodniu 48 w
    porównaniu z grupami pacjentów leczonymi placebo oraz
    guselkumabem.
    • Odsetek pacjentów, którzy osiągną skalę IGA 0 lub 1 w tygodniu 48 w
    porównaniu z grupami pacjentów leczonymi placebo oraz guselkumabem
    • Odsetek pacjentów, którzy osiągną skalę PASI90 w tygodniu 24 w
    porównaniu z grupami pacjentów leczonymi adalimumabem oraz
    guselkumabem
    • Odsetek pacjentów, którzy osiągną skalę PASI90 w tygodniu 48 w
    porównaniu z grupami pacjentów leczonymi adalimumabem oraz
    guselkumabem
    • Zmiana w stosunku do baseline skali DLQI wobec wyniku w tygodniu
    16, 24 w porównaniu z grupami pacjentów leczonymi adalimumabem
    oraz guselkumabem.
    • Odsetek pacjentów, którzy osiągną skalę IGA 0 w tygodniu 16 w
    porównaniu z grupami pacjentów leczonymi adalimumabem oraz
    guselkumabem
    • Odsetek pacjentów, którzy osiągną skalę PASI90 w tygodniu 16 w
    porównaniu z grupami pacjentów leczonymi adalimumabem oraz
    guselkumabem
    • Odsetek pacjentów, którzy osiągną skalę PASI75 w tygodniu 16 w
    porównaniu z grupami pacjentów leczonymi adalimumabem oraz
    guselkumabem
    • Odsetek pacjentów, którzy osiągnęli wynik skali ss-IGA 0 lub 1 z co
    najmniej 2 stopniową poprawą od baseline do tygodnia 16, w
    porównaniu z grupami pacjentów leczonymi adalimumabem oraz
    guselkumabem
    • Zmiana oceny w skali PSSD od baseline do tygodnia 16 w porównaniu
    z grupami pacjentów leczonymi adalimumabem oraz guselkumabem
    • Odsetek pacjentów, którzy osiągnęli wynik skali PSSD 0 w tygodniu
    24, w porównaniu z grupami pacjentów leczonymi adalimumabem oraz
    guselkumabem wśród zrandomizowanych pacjentów w wyjściowym
    wynikiem PSSD równym lub większym 1.
    Inne drugorzędowe punkty końcowe – porównania placebo 9guselkumab
    vs placebo i adalimumab vs placebo)
    • Odsetek pacjentów, którzy osiągnęli wynik skali IGA 0 i odsetek
    pacjentów, którzy osiągnęli wynik skali IGA 2 lub mniej w tygodniu 16
    • Odsetek pacjentów, którzy osiągnęli wynik skali PASI 100, PASI 75 i
    PASI 50 w tygodniu 16.
    • Procentowy odsetek poprawy od baseline do tygodnia 16 w skali
    PASI.
    • Odsetek pacjentów, którzy osiągnęli wynik skali DLQI 0 lub 1 w
    tygodniu 16 wśród pacjentów zrandomizowanych z wynikiem
    wyjsciowym skali DLQI powyżej 1
    • Odsetek pacjentów z redukcją wyniku skali DLQI o 5 lub więcej
    punktów w tygodniu 16.
    • Procentowa poprawa od baseline do tygodnia 16 w skali NAPSI w
    tygodniu16 wśród pacjentów z łuszczycą paznokci.
    • Odsetek pacjentów, którzy osiągnęli f-PGA 0 lub 1 i mają co najmniej
    1 –stopniową poprawę w skali f-PGA w tygodniu 16 w porównaniu do
    baseline, wśród pacjentów z wyjściowym wynikiem f-PGA większym lub
    równym 2.
    • Odsetek pacjentów, którzy osiągnęli wynik skali PSSD w tygodniu 16
    wśród zrandomizowanych pacjentów z wyjściowym wynikiem PSSD
    równe lub większe 1.
    • Zmiana w porównaniu do baseline w tygodniu 16 w poszczególnych
    składnikach skali PSSD
    • Odsetek pacjentów, którzy osiągnęli wynik skali PSSD w tygodniu 16
    wśród zrandomizowanych pacjentów z wyjściowym wynikiem PSSD
    równe lub większe 1
    • Odsetek pacjentów, którzy osiągnęli wynik skali hf-PGA 0 lub 1 z co
    najmiej 2 stopniową skalą poprawy od baseline do tygodnia 16 wśród
    pacjentów z łuszczycą dłoni i stóp i wynikiem hf-PGA 2 lub więcej na
    baseline.
    Guselkumab vs Adalimumab
    • Odsetek pacjentów, którzy osiągnęli wynik skali PASI 75 i PASI 100 w
    tygodniach 24 i 48.
    • Odsetek pacjentów, którzy osiągnęli wynik skali ss-IGA 0 lub 1 z co
    najmniej 2 –stopniową poprawą od baseline do tygodnia 48 wśród
    zrandomizowanych pacjentów z łuszczycą głowy i wynikiem skali ss-IGA
    równe lub większe 2.
    • Procentowa poprawa od baseline do tygodniach 24 i 48 w skali NAPSI
    wśród zrandomizowanych pacjentów z łuszczycą paznokci.
    • Odsetek pacjentów, którzy osiągnęli wynik skali f-PGA 0 lub 1 z co
    najmniej 1 –stopniową poprawą od baseline w tygodniach 24 i 48 wśród
    pacjentów zrandomizowanych z wynikiem skali fPGA równe lub większy
    2 na baseline.
    • Odsetek pacjentów, którzy osiągnęli wynik skali hf-PGA 0 lub 1 z co
    najmniej 2 stopniową poprawą w stosunku do baseline w tygodniach 24 i
    48 wśród pacjentów zrandomizowanych z łuszczycą stóp i dloni i
    wynikiem skali hf-PGA 2 lub więcej na baseline.
    • Odsetek pacjentów, którzy osiągnęli wynik skali DLQI 0 lub 1 w
    tygodniach 24 i 48 wśród pacjentów zrandomizowanych z wyjściową
    wartością DLQI powyżej 1.
    Więcej drugorzędowych punktów koncowych znajduje się w protokole.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Week 16/ Week 24/ Week 48
    Wizyty w tygodniach 16/24/48
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA45
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Germany
    Hungary
    Korea, Republic of
    Poland
    Russian Federation
    Spain
    Taiwan
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days12
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months8
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 675
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 75
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state150
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 300
    F.4.2.2In the whole clinical trial 750
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    There are no plans for additional treatment or care after the subject ends (or has ended) participation in the trial.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-11-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-09-24
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2020-06-17
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA